-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 15, Haisco issued an announcement stating that the company has recently received the "Notice of Acceptance" for HSK36212 capsules (1mg; 5mg; 30mg) issued by the State Food and Drug Administration; the application is for domestically produced drug registration clinical trials
.
HSK36212 capsule is a small molecule agonist of nuclear factor-related factor pathway
.
It is clinically intended for the treatment of chronic kidney disease and kidney disease caused by acute kidney injury
Preclinical studies have shown that HSK36212 capsules can inhibit the expression of genes related to renal injury and fibrosis at the molecular level in animal models of acute kidney injury and chronic kidney disease; Reducing the inflammatory response, in the detection of renal biochemical function, can increase the UPCR ratio and improve blood biochemical indicators, showing a huge potential for the treatment of renal disease